A multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable (UTD1) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depoxythilone (Primary) ; Docetaxel
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors BioStar

Most Recent Events

19 Jun 2023 New trial record
15 Jun 2023 According to a Biostar media release, the company has received IND approval for this study form the US FDA. The study is going to be conducted at about 50 sites in about 10 countries and regions across US, Europe and Asia -Pacific.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight